Breaking News

Genmab, Lilly Enter DuoBody Platform Pact

To explore Genmab’s DuoBody for creation of antibodies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Genmab has entered a research collaboration with Eli Lilly and Co. for the use Genmab’s DuoBody technology platform to create bispecific antibodies. Lilly will initially evaluate the DuoBody technology platform in house. Financial terms were not disclosed.    Jan van de Winkel, Ph.D., chief executive officer of Genmab, commented, “Our DuoBody platform continues to attract strong interest from the pharmaceutical industry and we are pleased to enter our fifth partnership for this innovative ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters